LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
LYELL IMMUNOPHARMA INC
NASDAQ:LYEL (11/22/2024, 8:00:00 PM)
After market: 0.9798 +0.03 (+3.14%)0.95
+0.03 (+3.64%)
Company Profile
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2021-06-17. The firm's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The firm is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.
Company Info
LYELL IMMUNOPHARMA INC
201 Haskins Way, Suite 301
South San Francisco CALIFORNIA
P: 16506950677
CEO: Elizabeth Homans
Employees: 224
Website: https://lyell.com/
LYEL News
3 days ago - ChartmillGapping stocks in Wednesday's sessionGap analysis on 2024-11-20: gap up and gap down stocks in today's session.
16 days ago - Lyell Immunopharma, IncLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 202418 days ago - Lyell Immunopharma, IncLyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting18 days ago - Lyell Immunopharma, IncLyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual MeetingSOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of...
23 days ago - Lyell Immunopharma, IncLyell Immunopharma Completes Acquisition of ImmPACT Bio23 days ago - Lyell Immunopharma, IncLyell Immunopharma Completes Acquisition of ImmPACT BioAcquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to...
LYEL Twits
Here you can normally see the latest stock twits on LYEL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
